EUCAST recommended strains for internal quality control
|
|
|
- Jonah French
- 6 years ago
- Views:
Transcription
1 EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC 785 ATCC 91 ATCC 91 ATCC 9619 NCTC Version number Strain Changes 1.1, ATCC 91 Erythromycin corrected from to 15 μg and ciprofloxacin from 0 to 5 μg. 1., ATCC 59 QC ranges updated : Cefadroxil, doripenem and nitrofurantoin. Antibiotics added: Amoxicillin, ampicillin-sulbactam, cefalexin, cefixime, ceftriaxone, colistin, fosfomycin, levofloxacin, netilmicin, ofloxacin, piperacillin, ticarcillin and ticarcillin-clavulanic acid. ATCC 785 ATCC 91 ATCC 91 ATCC 9619 NCTC 868 Antibiotics removed : Cefoxitin and tetracycline. QC ranges updated : Doripenem Antibiotics added: Colistin, fosfomycin, levofloxacin, netilmicin, piperacillin, ticarcillin and ticarcillin-clavulanic acid. QC ranges updated : Moxifloxacin and vancomycin (only ranges for vancomycin). Antibiotics added: Azithromycin, clarithromycin, daptomycin, doxycycline, fosfomycin, levofloxacin, minocycline, netilmicin, ofloxacin, quinupristindalfopristin and teicoplanin. Antibiotics removed : Amoxicillin-clavulanic acid, cefepime, cefotaxime, cefpodoxime, cefuroxime, ertapenem, meropenem, oxacillin and piperacillin-tazobactam. Antibiotics added: Quinupristin-dalfopristin. Antibiotics removed : Amoxicillin-clavulanic acid, chloramphenicol, ciprofloxacin, erythromycin, moxifloxacin, norfloxacin, piperacillintazobactam, rifampicin and tobramycin. QC ranges updated : Tetracycline (zone) and linezolid (). Azithromycin and clarithromycin (only ranges). Antibiotics added: Benzylpenicillin, ciprofloxacin, daptomycin, doxycycline, minocycline, teicoplanin and telithromycin. Antibiotics removed : Piperacillin-tazobactam. QC ranges updated : Trimethoprim-sulfamethoxazole Antibiotics added: Amoxicillin, ampicillin-sulbactam, minocycline and telithromycin. Antibiotics removed : Azithromycin, aztreonam, clarithromycin, piperacillin-tazobactam and tigecycline. 1 NCTC 868 is susceptible to beta-lactam antibiotics and easier to read on MH-F than the commonly recommended ATCC 97 which is a BLNAR with variable inhibition zones for beta-lactam antibiotics. Updated by EUCAST and/or CLSI. Antibiotics not in EUCAST Clinical Breakpoint Table or no data for ranges.
2 Escherichia coli ATCC 59 (NCTC 11, CIP 76., DSM 110, CCUG 1760) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing Target 1 Range Target 1 Range Amikacin Amoxicillin IP IP Amoxicillin-clavulanic acid / /1-8/ Ampicillin Ampicillin-sulbactam / /1-8/ Aztreonam Cefadroxil Cefalexin IP IP Cefepime Cefixime Cefotaxime Cefpodoxime Ceftazidime Ceftibuten Ceftriaxone Cefuroxime Chloramphenicol Ciprofloxacin Colistin Doripenem Fosfomycin Ertapenem Gentamicin Imipenem Levofloxacin Mecillinam Meropenem Moxifloxacin Nalidixic acid Netilmicin IP IP Nitrofurantoin Norfloxacin Ofloxacin Piperacillin Piperacillin-tazobactam / 1/-/ Ticarcillin Ticarcillin-clavulanic acid 8/ /-16/ Tigecycline Tobramycin Trimethoprim Trimethoprim-sulfamethoxazole 0.5/ International Standard ISO : 006. Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010. (Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0 different occasions on more than five batches of Mueller-Hinton agar from several manufacturers.) Ignore growth that may appear as a thin inner zone with ampicillin on some batches of Mueller-Hinton agars. 5 For test conditions, see Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010.
3 Pseudomonas aeruginosa ATCC 785 (NCTC 190, CIP , DSM 1117, CCUG 17619) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing Target 1 Range Target 1 Range Amikacin Aztreonam Cefepime Ceftazidime Ciprofloxacin Colistin Doripenem 0, Fosfomycin Gentamicin Imipenem Levofloxacin Meropenem Netilmicin Piperacillin Piperacillin-tazobactam -/ 1/-8/ Ticarcillin Ticarcillin-clavulanic acid 16/ 8/-/ Tobramycin International Standard ISO : 006. Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010. (Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0 different occasions on more than five batches of Mueller-Hinton agar from several manufacturers.) For test conditions, see Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010.
4 Staphylococcus aureus ATCC 91* (NCTC 197, CIP 109, DSM 569, CCUG 15915) * β-lactamase-producing strain (weak) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing Target 1 Range Target 1 Range Amikacin Azithromycin Benzylpenicillin unit Cefoxitin Chloramphenicol Ciprofloxacin 0, Clarithromycin 0, Clindamycin 0, Daptomycin Doxycycline 0, Erythromycin 0, Fosfomycin Fusidic acid 0, Gentamicin Levofloxacin IP IP Linezolid Minocycline IP IP Moxifloxacin Netilmicin Nitrofurantoin Norfloxacin Ofloxacin Quinupristin-dalfopristin 0, IP IP Rifampicin 0, Teicoplanin 0, Tetracycline Tigecycline Tobramycin Trimethoprim Trimethoprim-sulfamethoxazole 0.5/ Vancomycin International Standard ISO : 006. Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0 For test conditions, see Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010.
5 Enterococcus faecalis ATCC 91 (NCTC 1697, CIP 101, DSM 570, CCUG 9997) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing Target 1 Range Target 1 Range Ampicillin Gentamicin Imipenem Linezolid Nitrofurantoin Quinupristin-dalfopristin Teicoplanin 0, Tetracycline Tigecycline 5 0, Trimethoprim Trimethoprim-sulfamethoxazole 0.5/ Vancomycin International Standard ISO : 006. Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0 Screening disk for high-level aminoglycoside-resistance in enterococci. 5 For test conditions, see Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010.
6 Streptococcus pneumoniae ATCC 9619*/** (NCTC 1977, CIP 100, DSM 11967, CCUG 68) * Penicillin-intermediate strain ** Zone edges for S. pneumoniae on MH-F may be accompanied by α-haemolysis extending approximately 1 mm into the zone. Read growth, not haemolysis. With some batches of agar and some antibiotics the colonies at the zone edge lyse and the apparent width of haemolysis is considerably greater. The zone edge should be read as the edge of the lysed colonies indicated by a haze just inside the α-haemolysis. Mueller-Hinton agar + 5% horse blood and 0 mg/l β-nad, McFarland 0.5, 5% CO, 5±1ºC, 18±h. Read zone edges as the point showing no growth from the front with the lid removed and reflected light. Target 1 Range Target 1 Range Ampicillin 0, Azithromycin 0, Benzylpenicillin 0, unit Cefaclor Cefepime Cefotaxime 0, Cefpodoxime 0, Ceftriaxone 0, Cefuroxime 0, Chloramphenicol Ciprofloxacin Clarithromycin 0, Clindamycin 0, Daptomycin Doripenem 0, Doxycycline Ertapenem Erythromycin 0, Imipenem 0, Levofloxacin Linezolid Meropenem 0, Minocycline Moxifloxacin 0, Norfloxacin Ofloxacin Oxacillin Rifampicin 0, Teicoplanin Telithromycin Tetracycline 0, Tigecycline Trimethoprim-sulfamethoxazole 0.5/ / /.-1/ Vancomycin 0, International Standard ISO : 006. Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0 Clinical and Laboratory Standards Institute, M100-S0: 0:1, For test conditions, see Clinical and Laboratory Standards Institute, M100-S0: 0:1, 010.
7 Haemophilus influenzae NCTC 868 (CIP 5.9, CCUG 96) Mueller-Hinton agar + 5% horse blood and 0 mg/l β-nad, McFarland 0.5, 5% CO, 5±1ºC, 18±h. Read zone edges as the point showing no growth from the front with the lid removed and reflected light. Target Range Target 1 Range 1 Amoxicillin IP IP Amoxicillin-clavulanic acid IP IP Ampicillin IP IP 19-5 Ampicillin-sulbactam IP IP Cefaclor IP IP Cefepime IP IP Cefixime IP IP Cefotaxime IP IP Cefpodoxime IP IP Ceftibuten IP IP Ceftriaxone IP IP Cefuroxime IP IP Chloramphenicol IP IP Ciprofloxacin IP IP Doripenem IP IP Ertapenem IP IP Erythromycin IP IP Imipenem IP IP Levofloxacin IP IP Meropenem IP IP Minocycline IP IP 0 IP IP Moxifloxacin IP IP Nalidixic acid IP IP Ofloxacin IP IP Phenoxymethylpenicillin IP IP Rifampicin IP IP Telithromycin IP IP 15 IP IP Tetracycline IP IP Trimethoprim-sulfamethoxazole IP IP Data in bold/italics from repeated testing by EUCAST. Inhibition zone diameters were measured on at least 0
Routine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
What s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
Compliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
Compliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
AMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
British Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate
British Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method
Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
Antimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
January 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
January 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
ESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
BSAC standardized disc susceptibility testing method (version 8)
Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
Antimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
EUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
Performance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
Penicillins - EUCAST clinical MIC breakpoints (version 1.3)
EUCAST clinical MIC breakpoints - penicillins Penicillins - EUCAST clinical MIC breakpoints 2009-04-19 (version 1.3) Penicillins Click on antibiotic name to see wild type MIC distributions. Enterobacteriaceae
Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
- the details, where possible, of the antibiotic products these companies supply or have supplied.
Under the Freedom of Information Act 2000 please could you provide me with a list of all companies currently supplying antibiotics - or that have supplied antibiotics in the last three years - to Royal
Intrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
Concise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
Quality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
Antimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #116 (NQF 0058): Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.
Ref: FOI/CAD/ID 3459 27 June 2017 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act
This document is protected by international copyright laws.
Table 2C Table 2C. and s for Product Name: Infobase 2010 - Release Date: February 2010 60 Clinical and Laboratory Standards Institute. All rights reserved. Testing Conditions Medium: diffusion: MHA Broth
2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia
EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and
Antimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.
Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial
Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
Background and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
Version 13 January 2014
BSAC Methods for Antimicrobial Susceptibility Testing Version 13 January 2014 All enquiries to: Mandy Wootton Email: Mandy.Wootton@wales.nhs.uk Telephone: +44 (0) 2920 746581 Contents Page Working Party
EARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
Version 6, January 2007
BSAC Methods for Antimicrobial Susceptibility Testing Version 6, January 2007 All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews@swbh.nhs.uk 1 Contents Page Working Party members
QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
Version 9.1 March 2010
BSAC Methods for Antimicrobial Susceptibility Testing Version 9.1 March 2010 All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews@swbh.nhs.uk Contents Page Working Party members
Version 7, January 2008
BSAC Methods for Antimicrobial Susceptibility Testing Version 7, January 2008 All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews@swbh.nhs.uk 1 Contents Page Working Party members
EUCAST expert rules in antimicrobial susceptibility testing
REVIEW BACTERIOLOGY EUCAST expert rules in antimicrobial susceptibility testing R. Leclercq 1,2, R. Cantón 2,3,4, D. F. J. Brown 4, C. G. Giske 2,4,5, P. Heisig 2,6, A. P. MacGowan 4,7, J. W. Mouton 4,8,
CONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
Version 8 January 2009
BSAC Methods for Antimicrobial Susceptibility Testing All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews@swbh.nhs.uk 2 Contents Page Working Party members 5 Abstract 6 Preface
Childrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Anaerobes subcommittee EUCAST Subcommittee on breakpoints
GENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
Available online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
Version 10.1 April 2011
BSAC Methods for Antimicrobial Susceptibility Testing Version 10.1 April 2011 All enquiries to: Jenny Andrews at: + 44 (0) 121 507 5693 Email: jenny.andrews1@nhs.net Contents Page Working Party members
Int.J.Curr.Microbiol.App.Sci (2017) 6(11):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 2293-2299 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.272
MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
Should we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
Main objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
CONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
Version 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
RCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
Recommendations to take it forward!
Capacity Building and Strengthening of Hospital Infection Control to detect and prevent antimicrobial resistance in India AIIMS-ICMR-CDC EQAS Recommendations to take it forward! Top regional diagnostic
Understanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
Approach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method.
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.
CAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods
CAP Laboratory Improvement Programs Performance Accuracy of Antibacterial and Antifungal usceptibility Test Methods Report From the College of American Pathologists Microbiology urveys Program (001 003)
Antimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne
Antimicrobial susceptibility testing challenges Linda Joyce St Vincent s Hospital Melbourne Bacteria/antimicrobials without breakpoints (B.A.W.B.S.) Enterobacteriacae Pseudomonas aeruginosa, Acinetobacter
Mongolia September 2012
MICROBIOLOGY: bacterial resistance Roßburg / 9.9.22 MVZ DORTMUND - Dr.Eberhard u. Partner - MICROBIOLOGY bacterial resistance control, role of the laboratory MIKROBIOLOGY www.labmed.de / mikro@labmed.de
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS LABORATORIES ON THE FRONT LINE From the National Action Plan for Combating Antibiotic Resistant
2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
IMPORTANCE OF GLOBAL HARMONIZATION OF ANTIMICROBIAL SUSCEPTIBILITY TESTING IN CANADA FOR DEFINING ANTIMICROBIAL RESISTANCE
IMPORTANCE OF GLOBAL HARMONIZATION OF ANTIMICROBIAL SUSCEPTIBILITY TESTING IN CANADA FOR DEFINING ANTIMICROBIAL RESISTANCE Robert P. Rennie Professor Emeritus Laboratory Medicine and Pathology University
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017)
EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017) Questions on this document can be directed towards: Karl Mertens Scientific
Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
EUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
Indian Journal of Basic and Applied Medical Research; June 2016: Vol.-5, Issue- 3, P
Original article: Evaluation of antimicrobial sensitivity and resistance pattern of Gram positive and Gram negative bacteria to monitor drug resistance among clinical isolates 1Dr Razia Khatoon, 2 Mahak
Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are